Literature DB >> 22566140

Discovery of small molecules that bind to K-Ras and inhibit Sos-mediated activation.

Qi Sun1, Jason P Burke, Jason Phan, Michael C Burns, Edward T Olejniczak, Alex G Waterson, Taekyu Lee, Olivia W Rossanese, Stephen W Fesik.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22566140      PMCID： PMC3620661          DOI： 10.1002/anie.201201358

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN： 1433-7851            Impact factor:   15.336


× No keyword cloud information.
  17 in total

Review 1.  Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.

Authors:  Michelle R Arkin; James A Wells
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

2.  Molecular switch in signal transduction: reaction paths of the conformational changes in ras p21.

Authors:  J Ma; M Karplus
Journal:  Proc Natl Acad Sci U S A       Date:  1997-10-28       Impact factor: 11.205

Review 3.  Fragment-based screening using X-ray crystallography and NMR spectroscopy.

Authors:  Harren Jhoti; Anne Cleasby; Marcel Verdonk; Glyn Williams
Journal:  Curr Opin Chem Biol       Date:  2007-09-11       Impact factor: 8.822

4.  Discovering high-affinity ligands for proteins: SAR by NMR.

Authors:  S B Shuker; P J Hajduk; R P Meadows; S W Fesik
Journal:  Science       Date:  1996-11-29       Impact factor: 47.728

Review 5.  RAS oncogenes: weaving a tumorigenic web.

Authors:  Yuliya Pylayeva-Gupta; Elda Grabocka; Dafna Bar-Sagi
Journal:  Nat Rev Cancer       Date:  2011-10-13       Impact factor: 60.716

6.  Selenomethionine incorporation into a protein by cell-free synthesis.

Authors:  Takanori Kigawa; Emi Yamaguchi-Nunokawa; Koichiro Kodama; Takayoshi Matsuda; Takashi Yabuki; Natsuko Matsuda; Ryuichiro Ishitani; Osamu Nureki; Shigeyuki Yokoyama
Journal:  J Struct Funct Genomics       Date:  2002

7.  Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.

Authors:  Li-Chen Yen; Yih-Huei Uen; Deng-Chyang Wu; Chien-Yu Lu; Fang-Jung Yu; I-Chen Wu; Shiu-Ru Lin; Jaw-Yuan Wang
Journal:  Ann Surg       Date:  2010-02       Impact factor: 12.969

8.  Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers.

Authors:  Luigi Laghi; Ombretta Orbetegli; Paolo Bianchi; Alessandro Zerbi; Valerio Di Carlo; C Richard Boland; Alberto Malesci
Journal:  Oncogene       Date:  2002-06-20       Impact factor: 9.867

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

10.  An orthosteric inhibitor of the Ras-Sos interaction.

Authors:  Anupam Patgiri; Kamlesh K Yadav; Paramjit S Arora; Dafna Bar-Sagi
Journal:  Nat Chem Biol       Date:  2011-07-17       Impact factor: 15.040
View more
  172 in total

Review 1.  How to Target Activated Ras Proteins: Direct Inhibition vs. Induced Mislocalization.

Authors:  Ethan J Brock; Kyungmin Ji; John J Reiners; Raymond R Mattingly
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

Review 2.  Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view.

Authors:  Shaoyong Lu; Hyunbum Jang; Shuo Gu; Jian Zhang; Ruth Nussinov
Journal:  Chem Soc Rev       Date:  2016-07-11       Impact factor: 54.564

Review 3.  RAS-targeted therapies: is the undruggable drugged?

Authors:  Amanda R Moore; Scott C Rosenberg; Frank McCormick; Shiva Malek
Journal:  Nat Rev Drug Discov       Date:  2020-06-11       Impact factor: 84.694

Review 4.  KRAS as a Therapeutic Target.

Authors:  Frank McCormick
Journal:  Clin Cancer Res       Date:  2015-04-15       Impact factor: 12.531

5.  Drug discovery: Pocket of opportunity.

Authors:  Gideon Bollag; Chao Zhang
Journal:  Nature       Date:  2013-11-20       Impact factor: 49.962

6.  A novel terpenoid class for prevention and treatment of KRAS-driven cancers: Comprehensive analysis using in situ, in vitro, and in vivo model systems.

Authors:  Arsheed A Ganaie; Hifzur R Siddique; Ishfaq A Sheikh; Aijaz Parray; Lei Wang; Jayanth Panyam; Peter W Villalta; Yibin Deng; Badrinath R Konety; Mohammad Saleem
Journal:  Mol Carcinog       Date:  2020-04-15       Impact factor: 4.784

7.  miR-1298 Inhibits Mutant KRAS-Driven Tumor Growth by Repressing FAK and LAMB3.

Authors:  Ying Zhou; Jason Dang; Kung-Yen Chang; Edwin Yau; Pedro Aza-Blanc; Jorge Moscat; Tariq M Rana
Journal:  Cancer Res       Date:  2016-10-01       Impact factor: 12.701

8.  Approach for targeting Ras with small molecules that activate SOS-mediated nucleotide exchange.

Authors:  Michael C Burns; Qi Sun; R Nathan Daniels; DeMarco Camper; J Phillip Kennedy; Jason Phan; Edward T Olejniczak; Taekyu Lee; Alex G Waterson; Olivia W Rossanese; Stephen W Fesik
Journal:  Proc Natl Acad Sci U S A       Date:  2014-02-18       Impact factor: 11.205

9.  Inhibition of Ras-Effector Interaction by Cyclic Peptides.

Authors:  Xianghong Wu; Punit Upadhyaya; Miguel A Villalona-Calero; Roger Briesewitz; Dehua Pei
Journal:  Medchemcomm       Date:  2013-02-01       Impact factor: 3.597

10.  Overview of simulation studies on the enzymatic activity and conformational dynamics of the GTPase Ras.

Authors:  Priyanka Prakash; Alemayehu A Gorfe
Journal:  Mol Simul       Date:  2014-03-19       Impact factor: 2.178
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.